What question did this study set out to answer?

This research aims to identify prognostic subgroups and evaluate treatment outcomes for estrogen receptor low-positive metastatic breast cancer patients.

February 13, 2026Open Access

Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer

Key Points

This research aims to identify prognostic subgroups and evaluate treatment outcomes for estrogen receptor low-positive metastatic breast cancer patients.
Analyze survival data based on PR-positivity among ER low-positive patients and ER-negative patients.
Evaluate the suitability of first-line endocrine therapy in ER low-positive patients.
PR-positivity correlates with improved survival for ER low-positive patients compared to ER-negative patients.
Endocrine therapy shows promise as a viable first-line treatment for ER low-positive metastatic cases.

Abstract

PR-positivity identifies a subgroup of ER low-positive dnMBC patients with superior survival compared to ER-negative patients. First-line treatment incorporating endocrine therapy may be appropriate to consider for ER low-positive patients.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Madelyn Klugman

Maya Aboumrad

Ruizhe Chen

Journals

Breast Cancer Research and Treatment

Actions

Institutions

Johns Hopkins University

Johns Hopkins Medicine

Sidney Kimmel Comprehensive Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study